Advertisement
Screener

PASSAGE BIO, INC. (PASG) Quick Ratio

2.8 / 5 stars · 68/120 Roast Me

Passage BIO, Inc. Quick Ratio

The quick ratio is a stricter test of whether a company can pay the bills due within a year, counting only assets that are already cash or close to it. It is cash, marketable securities and receivables divided by current liabilities, shown as a multiple, with both amounts in the table. It is the current ratio with inventory and other assets that take longer to turn into cash removed, so it is never higher than the current ratio. A company that does not report one of the inputs has no point for that date rather than an estimated one. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.

  • Passage BIO, Inc. quick ratio for the quarter ending 2026-06-30 was 1.17, a 59.94% decline year-over-year.
  • Passage BIO, Inc. quick ratio for the quarter ending 2026-03-31 was 1.66, a 53.35% decline year-over-year.
  • Passage BIO, Inc. quick ratio for the quarter ending 2025-12-31 was 2.01, a 3.37% increase year-over-year.
  • Passage BIO, Inc. quick ratio for the quarter ending 2025-09-30 was 2.37, a 24.53% increase year-over-year.
  • Passage BIO, Inc. quick ratio for fiscal 2025 was 2.01, a 3.37% increase from fiscal 2024.
  • Passage BIO, Inc. quick ratio for fiscal 2024 was 1.94, a 46.06% increase from fiscal 2023.
  • Passage BIO, Inc. quick ratio for fiscal 2023 was 1.33, a 29.54% decline from fiscal 2022.
  • Passage BIO, Inc. quick ratio for fiscal 2022 was 1.89, a 56.87% decline from fiscal 2021.
Available history
2019-12-31 to 2026-06-30
Data captured

Historical Quick Ratio

DateQuick RatioQuick assetsCurrent liabilities
2026-06-301.17$24.16M$20.72M
2026-03-311.66$33.34M$20.1M
2025-12-312.01$46.3M$23.08M
2025-09-302.37$52.77M$22.25M
2025-06-302.91$57.63M$19.8M
2025-03-313.55$63.36M$17.83M
2024-12-311.94$37.57M$19.36M
2024-09-301.91$32.29M$16.95M
2024-06-302$24.77M$12.39M
2024-03-312.86$36.77M$12.84M
2023-12-311.33$21.71M$16.34M
2023-09-301.69$33.58M$19.81M
2023-06-301.52$30.29M$19.87M
2023-03-311.94$33.37M$17.24M
2022-12-311.89$34.6M$18.35M
2022-09-302.89$62.57M$21.62M
2022-06-303.36$91.13M$27.13M
2022-03-313.7$101.61M$27.48M
2021-12-314.37$128.97M$29.5M
2021-09-307.32$162.89M$22.25M
2021-06-306.89$215.46M$31.25M
2021-03-3112.82$249.52M$19.47M
2020-12-316.38$135M$21.18M
2020-09-3010.5$200.57M$19.1M
2020-06-3025.01$353.42M$14.13M
2020-03-3170.17$366.83M$5.23M
2019-12-3143.16$158.87M$3.68M

Annual Quick Ratio

DateQuick RatioQuick assetsCurrent liabilities
2025-12-312.01$46.3M$23.08M
2024-12-311.94$37.57M$19.36M
2023-12-311.33$21.71M$16.34M
2022-12-311.89$34.6M$18.35M
2021-12-314.37$128.97M$29.5M
2020-12-316.38$135M$21.18M
2019-12-3143.16$158.87M$3.68M

Similar stocks

Stock NameCountryMarket CapPE Ratio
DYADIC INTERNATIONAL INC (DYAI)United States$0.016B
BioCardia, Inc. (BCDA)United States$0.016B
Pluri Inc. (PLUR)$0.014B
INTENSITY THERAPEUTICS, INC. (INTS)United States$0.013B-1.08
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)United States$0.013B-1.05
IN8BIO, INC. (INAB)United States$0.012B-0.76
Jasper Therapeutics, Inc. (JSPR)United States$0.020B-0.37
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
Estrella Immunopharma, Inc. (ESLA)United States$0.020B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23